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Abstract
In 2017, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that betaine
as a novel food (NF) is safe to be used at a maximum intake level of 6 mg/kg body weight per day in
addition to the intake from the background diet. Following the present request from the European
Commission, the EFSA NDA Panel was asked to deliver a scientiﬁc opinion on betaine by carrying out
the assessment for the revised uses and use levels of betaine as proposed by the applicant. Thus,
EFSA performed an intake assessment based on individual data from the EFSA Comprehensive
European Food Consumption Database and the new proposed uses of the NF for the general
population. The resulting ranges for the mean and high-level estimated intakes of betaine for the
general population do not exceed the safe level of intake previously established. The Panel concludes
that the NF, betaine, is safe under the new proposed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 2 November 2018, the company DuPont Nutritional Biosciences ApS, submitted a request to the
European Commission in accordance with Article 10 of Regulation (EU) No 2015/22831 to place on the
EU market betaine as a novel food (NF).
This application follows the 2015 application by the same company to Finland to place betaine on
the EU market as a NF ingredient under Article 4 of Regulation (EU) No 258/1997.2
Following the initial assessment of this application by Finland, and the reasoned objections raised
by Member States, the Commission requested EFSA to assess the safety of betaine as a NF ingredient.
In its opinion of 25 October 2017, EFSA concluded that betaine would pose no safety concerns if the
total daily intake from all uses would not exceed 400 mg/day.
The application submitted on 2 November 2018 contains revised use and intake concentrations for
betaine as a NF aligned with the maximum level of 400 mg/day deemed to be safe by EFSA.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientiﬁc opinion by carrying out the assessment for the
revised uses and intakes of betaine when used as a NF.
In doing so, EFSA should take into account its 25 October 2017 opinion on betaine as a NF which
established a maximum daily intake of 400 mg/day of betaine.
1.2. Interpretation of the Terms of Reference
The EFSA opinion adopted on 25 October 2017 has been amended to express the maximum safe
intake level of 400 mg per day on a mg/kg body weight (bw) basis (i.e. 6 mg/kg bw per day).
Thus, in order to address the present mandate, EFSA carried out the assessment for the revised
uses and use levels of betaine when used as a NF by considering the established maximum safe intake
level of 6 mg/kg bw per day in addition to the intake from the background diet.
2. Data and methodologies
2.1. Data
The assessment of the safety of betaine at the new proposed uses and use levels is based on the
new data provided by the applicant and the scientiﬁc opinion on the safety of betaine as a NF which
was adopted by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) in 2017 (EFSA
NDA Panel, 2017).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications3 and the
principles described in the relevant existing guidance documents from the EFSA Scientiﬁc Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.4
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 Regulation (EU) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
3 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283.
EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientiﬁc
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use and is not an assessment of the efﬁcacy of the NF with regard to any
claimed beneﬁt.
3. Assessment
On 25 October 2017, the EFSA NDA Panel adopted the scientiﬁc opinion on the safety of betaine as
a NF when added to a variety of foods (EFSA NDA Panel, 2017). In that scientiﬁc opinion, the
Panel concluded that an amount up to 6 mg/kg bw per day of betaine in addition to the intake from
the background diet is considered as safe.
In order to address the present mandate, the EFSA NDA Panel is asked to perform the assessment
of the new uses and use levels of betaine as proposed by the applicant.
3.1. Target population
The target population proposed by the applicant is sportspeople above 10 years of age.
According to Article 5(6) of Regulation (EU) 2017/2469, where it cannot be excluded that a NF
intended for a particular group of the population would be also consumed by other groups of the
population the safety data provided shall also cover those groups. Thus, the Panel considers the
general population as the target population.
3.2. Proposed uses and use levels
The new intended uses and use levels of betaine as proposed by the applicant are presented in
Table 1.
3.3. Anticipated intake
3.3.1. Intake from the proposed uses and use levels of the NF
The applicant provided an intake assessment of the NF based on the new proposed uses and use
levels as indicated in Table 1 and the United Kingdom National Diet and Nutrition Survey (UK NDNS)
dietary survey, years 1–6 (2008–2014) (Department of Health, 2014, 2016; NatCen Social Research/
MRC Elsie Widdowson Laboratory/University College London, Medical School, 2017).
To evaluate the intake of betaine, EFSA performed a reﬁned intake assessment based on individual
data from the EFSA Comprehensive European Food Consumption Database, which is based on EU
dietary surveys (EFSA, 2011). As indicated in Section 3.1, the general population, which includes
sportspeople, was considered by EFSA in its intake assessment. Table 2 presents the food categories
according to the FoodEx2 classiﬁcation system and the maximum use levels of the NF which were used
for the reﬁned intake assessment performed by EFSA (European Food Safety Authority, 2015). For the
entry ‘Protein and protein components for sports people’, which include drink powders, EFSA used
the maximum use level of the NF in powders prior to be reconstituted to a solution, as indicated by
Table 1: Uses and maximum use levels of the NF as proposed by the applicant
Proposed use Maximum use level of the NF (mg/100 g)(a)
Drink powders targeted to athletes 60
Isotonic ready-to-drink beverages targeted to athletes 60
Protein and cereal bars targeted to athletes(b) 500
Meal replacements targeted to athletes 20
Total diet replacement foods for weight control as
deﬁned under Regulation (EU) No 609/2013
500 (bar); 136 (soup); 188 (porridge); 60 (beverages)
Foods for Special Medical Purposes, deﬁned by
Regulation (EU) No 609/2013, excluding foods for
infants and young children
400 mg/day(c)
(a): Use levels all expressed as consumed (i.e. as diluted).
(b): In order to increase the number of consumers (to increase statistical reliability of the results), all protein and cereals bars
were included in the assessment.
(c): Not included in intake assessment as dose is per daily serving and provided under medical supervision. Products will be
labelled to indicate maximum daily dose.
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the applicant. For the entry ‘Food for sporting people’ and ‘Carbohydrate-rich energy food products for
sports people’, which mainly include bars, EFSA used the proposed maximum use levels for cereal
bars. The uses as ‘Meal replacements targeted to athletes’ and ‘Total diet replacement foods for
weight control’ were allocated to the FoodEx2 categories ‘Food for weight reduction’ and ‘Single meal
replacement for weight reduction’.
Table 3 presents the ranges of the estimated daily intake of betaine among the EU dietary surveys
(all subjects) performed by EFSA on a mg/kg bw per day basis.
The Panel notes that the mean and high-level (95th percentile) estimated intakes of betaine for the
general population do not exceed the safe level of intake as previously established by the NDA Panel,
i.e. 6 mg/kg bw per day in addition to the intake from the background diet (EFSA NDA Panel, 2017).
The Panel notes the main source of intake of the NF from the new proposed uses: cereal bars in
infants and toddlers; cereal bars and isotonic and sport drinks in other children; isotonic and sport
drinks and energy drinks in adolescents; protein and protein components and food for weight
reduction in adults; cereal bars and protein and protein components in elderly people. A detailed
description of the contribution of each food category to the estimated intake of the NF for each
population group from each EU dietary survey is available in the excel ﬁle annexed to this scientiﬁc
opinion (under supporting information).
Table 2: Food categories according to FoodEx2 classiﬁcation and maximum use levels of the NF
used in the intake assessment performed with the EFSA Comprehensive European Food
Consumption Database
FoodEx2 code FoodEx2 category
Maximum use level of the NF
(mg/100 g)
A03RX Food for sporting people 500
A03RY Carbohydrate-rich energy food products for sports
people
500
A03RZ Carbohydrate-electrolyte solutions for sports people 60(a)
A03SA Protein and protein components for sports people 1,080(b)
A03FZ Functional drinks 60(a)
A03GA Energy drinks 60(a)
A03GB Isotonic and sport drinks 60(a)
A00EY Cereal bars 500
A00FA Cereal bars mixed 500
A00EZ Cereal bars plain 500
A03RS Food for weight reduction 500
A03RV Single meal replacement for weight reduction 500
(a): Maximum use level of the NF as consumed (i.e. as diluted).
(b): Maximum use level of the NF in powders (to be reconstituted to obtain a maximum use level of 60 mg/100 g in the ﬁnal
solution).
Table 3: Ranges among EU surveys of the estimated daily intake of the NF (mg/kg bw per day),
based on the EFSA Comprehensive European Food Consumption Database
Population
groups
Number of EU
dietary surveys
Estimated intake of the NF–all subjects
(mg/kg bw per day)
Range of means
(minimum and maximum)
across EU dietary surveys
Range of 95th percentile
(minimum and maximum)
across EU dietary surveys
Infants
(4–11 months)
11 0.00–0.05 0.00–0.00(a)
Toddlers
(12–35 months)
14 0.00–0.63 0.00–5.48
Other children
(3–9 years)
19 0.00–0.41 0.00–2.76
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3.3.2. Intake from other sources
As reported in the previous opinion in 2017, betaine-containing food supplements (with serving size
up to 1.5 g of betaine) are currently available in the EU market for sports people.
4. Discussion
In 2017, in its scientiﬁc opinion on betaine, the Panel concluded that an amount up to 6 mg/kg bw
per day of betaine in addition to the intake from the background diet is considered safe (EFSA NDA
Panel, 2017).
The intake assessment of betaine based on the new proposed uses and use levels indicated that
the mean and high-level (95th percentile) estimated intakes of betaine for the general population do
not exceed the safe level of intake as previously established by the NDA Panel. The Panel considers
the NF as safe, at the new proposed uses and use levels in the general population.
Regarding ‘Foods for Special Medical Purposes’, the Panel considers that the proposed maximum
daily intake of 400 mg/day is safe for adults only, as for individuals below 18 years of age the
proposed maximum daily intake exceeds the safe level of 6 mg/kg bw.
The Panel also notes that the consumption of some of the food supplements containing betaine
currently on the EU market could, on their own, result in intakes of betaine higher than those
considered safe by the Panel.
5. Conclusions
The Panel concludes that the NF, betaine, is safe under the new proposed conditions of use.
However, if used in conjunction with food supplements containing betaine, the Panel notes that the
safe level of intake may be exceeded.
Documentation provided to EFSA
1) Letter from the European Commission to EFSA with the request to provide a scientiﬁc
opinion on betaine by carrying out the assessment for the revised uses and intakes of
betaine when used as a NF. Ref. Ares(2018)6550422, dated 19/12/2018.
2) On 19/12/2018, a valid application on betaine, which was submitted by DuPont Nutrition
Biosciences ApS, was made available to EFSA by the European Commission through the
Commission e-submission portal (NF 2018/0685) and the scientiﬁc evaluation procedure
started.
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